TY - JOUR
T1 - Differential Effects of High-Dose Magnetic Seizure Therapy and Electroconvulsive Shock on Cognitive Function
AU - Spellman, Timothy
AU - McClintock, Shawn M.
AU - Terrace, Herbert
AU - Luber, Bruce
AU - Husain, Mustafa M.
AU - Lisanby, Sarah H.
N1 - Funding Information:
For work unrelated to the present study, Dr. Lisanby has received research support from Magstim Company, Neuronetics, Cyberonics, NIH, American Federation for Aging Research, NARSAD, Stanley Medical Research Foundation, Defense Advanced Research Projects Agency, and the New York State Office of Science, Technology, and Academic Research. Dr. McClintock has received funding from NIH. Dr. Husain has received research support from the NIMH, Stanley Medical Research Institute, Cyberonics, Pfizer (in process), Neuronetics, Magstim, and Medtronics (potential research sponsor); he has served on Advisory Boards for AstraZeneka, VersusMed, Avinar, Boston Scientific, MEASURE, Bristol-Meyer-Squibb; and Clinical Advisors and on speakers bureaus for Cyberonics, Avinar, Cerebrio, AstraZeneka, Bristol-Meyers-Squibb, Optima/Forrest Pharmaceuticals, Glaxo-Smith-Kline, Forrest Pharmaceuticals, and Janssen. Timothy Spellman, Herb Terrace, Shawn McClintock, and Bruce Luber have no conflicts or potential conflicts to report.
Funding Information:
This study was supported by National Institute of Mental Health (NIMH) R01 MH60884. Support for the development of magnetic seizure therapy has also come from the Stanley Medical Research Foundation, American Federation for Aging Research / Beeson Scholars Program, and the National Alliance for Research on Schizophrenia and Depression (NARSAD).
PY - 2008/6/15
Y1 - 2008/6/15
N2 - Background: Magnetic seizure therapy (MST) is under investigation as an alternative form of convulsive therapy that induces more focal seizures and spares cortical regions involved in memory. With a newly expanded version of the Columbia University Primate Cognitive Profile, we compared the cognitive effects of high-dose MST delivered at 100 Hz (6 × seizure threshold) with electroconvulsive shock (ECS) delivered at 2.5 × seizure threshold. Methods: Daily high-dose MST, ECS, and sham (anesthesia-only) were administered for 4 weeks each in a within-subject crossover design. Rhesus macaques (n = 3) were trained on five cognitive tasks assessing automatic memory, anterograde learning and memory, combined anterograde and retrograde simultaneous chaining, and spatial and serial working memory. Acutely after each intervention, monkeys were tested on the cognitive battery twice daily, separated by a 3-hour retention interval. Results: Subjects were slower to complete criterion tasks (p values < .0001) after ECS, compared with sham and high-dose MST. Moreover, time to task-completion after high-dose MST did not differ from sham. Of six measures of accuracy, treatment effects were found in four; in all of these, ECS but not MST fared worse than sham. On all accuracy and time to completion measurements, subjects performed as well after high-dose MST as subjects from a previous study on moderate-dose MST. Conclusions: These findings provide evidence that high-dose MST results in benign acute cognitive side-effect profile relative to ECS and are in line with our previous studies.
AB - Background: Magnetic seizure therapy (MST) is under investigation as an alternative form of convulsive therapy that induces more focal seizures and spares cortical regions involved in memory. With a newly expanded version of the Columbia University Primate Cognitive Profile, we compared the cognitive effects of high-dose MST delivered at 100 Hz (6 × seizure threshold) with electroconvulsive shock (ECS) delivered at 2.5 × seizure threshold. Methods: Daily high-dose MST, ECS, and sham (anesthesia-only) were administered for 4 weeks each in a within-subject crossover design. Rhesus macaques (n = 3) were trained on five cognitive tasks assessing automatic memory, anterograde learning and memory, combined anterograde and retrograde simultaneous chaining, and spatial and serial working memory. Acutely after each intervention, monkeys were tested on the cognitive battery twice daily, separated by a 3-hour retention interval. Results: Subjects were slower to complete criterion tasks (p values < .0001) after ECS, compared with sham and high-dose MST. Moreover, time to task-completion after high-dose MST did not differ from sham. Of six measures of accuracy, treatment effects were found in four; in all of these, ECS but not MST fared worse than sham. On all accuracy and time to completion measurements, subjects performed as well after high-dose MST as subjects from a previous study on moderate-dose MST. Conclusions: These findings provide evidence that high-dose MST results in benign acute cognitive side-effect profile relative to ECS and are in line with our previous studies.
KW - Cognitive
KW - ECT
KW - TMS
KW - impairment
KW - magnetic
KW - seizure
UR - http://www.scopus.com/inward/record.url?scp=44349149816&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44349149816&partnerID=8YFLogxK
U2 - 10.1016/j.biopsych.2007.11.024
DO - 10.1016/j.biopsych.2007.11.024
M3 - Article
C2 - 18262171
AN - SCOPUS:44349149816
SN - 0006-3223
VL - 63
SP - 1163
EP - 1170
JO - Biological Psychiatry
JF - Biological Psychiatry
IS - 12
ER -